Skip to content
GLP-1 Desk
Menu

Head-to-head dispatch

Pallas Health vs Shapely

Two GLP-1 providers, one scorecard. Both are graded on the same six Desk Score dimensions — here is how they stack up, and which one fits you.

Dispatch #8Desk pick
Pallas Health

Pallas Health names all six of the pharmacies that dispense for it and two prescribing clinicians whose NPIs verify in the federal registry — then sells every GLP-1 on a single twelve-week prepay, so the advertised “/mo average” is one $597 or $897 charge divided by three.

Marked down on: There is no month-to-month rung for either compounded molecule — the funnel renders no cadence selector — so the advertised “$199/mo average” is a single $597 charge every twelve weeks divided by three

vs
Dispatch #340
Shapely

Shapely is a GLP-1 telehealth platform founded by Dr.

Marked down on: Currently available only in California, Florida, New York, and Texas — 46 states unserved despite announced expansion

Pallas Health takes this head-to-head with the higher Desk Score, 87/100 (B+) against 58/100 (C) for Shapely. Shapely still holds its ground where its strengths line up with yours.

Desk Score, dimension by dimension

Same six measured dimensions for both. The red flag marks the stronger side. See the methodology.

Pallas Health

87/100

B+

Overall

Shapely

58/100

C

Price transparency

78
54

State access

94
42

Molecule range

90
53

Onboarding speed

88
47

Support responsiveness

88
92

Licensing & trust

90
83

The spec sheet

FieldPallas HealthShapely
Semaglutide$199/mo average (compounded injectable; $597 billed every 12 weeks after $139 for the first 4 weeks; no month-to-month tier is sold)Not disclosed
Tirzepatide$299/mo average (compounded injectable; $897 billed every 12 weeks after $179 for the first 4 weeks; no month-to-month tier is sold)Not disclosed
CoverageAll 50 states + DC (async in 43; 7 states plus DC require one video visit)4 states
Brand-nameYesYes
Oral optionInjectable onlyInjectable only
Best forReaders who weight named pharmacies and independently verifiable prescribers above cash-flow flexibility, and who can absorb a $597 or $897 charge every twelve weeks rather than a monthly one.Readers who want insurance-accepted telehealth with compounded sema $99/mo and tirz $166/mo; CA, FL, NY, TX (expanding).
Desk Score87/100B+58/100C

The verdict

Desk pick — Pallas Health

Pallas Health takes this head-to-head with the higher Desk Score, 87/100 (B+) against 58/100 (C) for Shapely. Shapely still holds its ground where its strengths line up with yours.

Choose Pallas Health if…

Readers who weight named pharmacies and independently verifiable prescribers above cash-flow flexibility, and who can absorb a $597 or $897 charge every twelve weeks rather than a monthly one.

$199/mo average (compounded injectable; $597 billed every 12 weeks after $139 for the first 4 weeks; no month-to-month tier is sold) sema · $299/mo average (compounded injectable; $897 billed every 12 weeks after $179 for the first 4 weeks; no month-to-month tier is sold) tirz · All 50 states + DC (async in 43; 7 states plus DC require one video visit)

Choose Shapely if…

Readers who want insurance-accepted telehealth with compounded sema $99/mo and tirz $166/mo; CA, FL, NY, TX (expanding).

Not disclosed sema · Not disclosed tirz · 4 states

Assume any provider we list may compensate us — we may earn a referral commission at no extra cost to you, and what we file on a provider reads the same either way. Read full breakdowns: Pallas Health · Shapely.

Also here

CoreAge Rx tops every dispatch at 94/100

Whichever of these two you lean toward, the Desk's #1-rated provider outscores them both. The Desk's top dispatch: flat all-in pricing, both molecules, all 50 states — no teaser-rate traps.

More head-to-heads

Or see the full comparison hub and the complete ranking.

Pricing and verification reflect each provider's public disclosures at last scoring; the Desk Score is our editorial judgment per the methodology. Prices change — confirm on each provider's own site. Not medical advice; see our disclosure.